Voyager Therapeutics, Inc.
VYGR
$4.15
$0.030.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.59M | 15.34M | 13.37M | 5.20M | 6.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.59M | 15.34M | 13.37M | 5.20M | 6.47M |
| Cost of Revenue | 24.60M | 33.55M | 35.87M | 31.33M | 31.53M |
| Gross Profit | -22.01M | -18.22M | -22.50M | -26.13M | -25.05M |
| SG&A Expenses | 8.26M | 8.22M | 8.09M | 10.50M | 9.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.86M | 41.77M | 43.96M | 41.83M | 41.17M |
| Operating Income | -30.27M | -26.43M | -30.59M | -36.63M | -34.69M |
| Income Before Tax | -27.92M | -27.42M | -27.81M | -33.37M | -30.98M |
| Income Tax Expenses | 14.00K | 9.00K | 83.00K | 15.00K | 37.00K |
| Earnings from Continuing Operations | -27.94M | -27.43M | -27.89M | -33.38M | -31.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.94M | -27.43M | -27.89M | -33.38M | -31.02M |
| EBIT | -30.27M | -26.43M | -30.59M | -36.63M | -34.69M |
| EBITDA | -29.34M | -25.38M | -29.66M | -35.56M | -33.68M |
| EPS Basic | -0.47 | -0.47 | -0.47 | -0.57 | -0.53 |
| Normalized Basic EPS | -0.29 | -0.25 | -0.30 | -0.36 | -0.33 |
| EPS Diluted | -0.47 | -0.47 | -0.47 | -0.57 | -0.53 |
| Normalized Diluted EPS | -0.29 | -0.25 | -0.30 | -0.36 | -0.33 |
| Average Basic Shares Outstanding | 59.50M | 58.94M | 58.80M | 58.67M | 58.35M |
| Average Diluted Shares Outstanding | 59.50M | 58.94M | 58.80M | 58.67M | 58.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |